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Abstract The CCN family of matricellular signaling
regulators shares a common domain structure. Variants of
individual CCN proteins exist, which contain different
combinations of these domains. Although mRNA splicing
is likely to play a key role on CCN biology, this hypothesis
has not been thoroughly tested. In a recent report,
Hirschfeld and colleagues (Cancer Res 69:2082-90, 2009),
show that CCN1 (cyr61) mRNA is normally present in a
form in which intron 3 is retained. In cancers, or upon
hypoxia, intron 3 is removed resulting in the appearance of
CCN1 protein. The significance of this paper is discussed.
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The CCN family of matricellular signaling modifiers are
intimately involved with crucial biological processes, such
as proliferation, differentiation, survival, adhesion and
migration (Leask and Abraham 2006; Holbourn et al.
2008;M a s o n2009). As such, CCN proteins are key
contributors to process such as development, tissue remod-
eling, fibrosis and cancers. The CCN family of genes
comprises six members which possess specific, non
redundant functions despite their high degree of structural
identity (Leask and Abraham 2006; Kennedy et al. 2007).
The CCN proteins possess four distinct structural modules
(IGFBP, VWC, TSP1, and CT) which resemble, respec-
tively, Insulin-like Growth Factor Binding Proteins, the Von
Willebrand factor, Thrombospondin 1, and growth factors
that contain a cysteine knot motif [including platelet-
derived (PDGF), nerve growth factor (NGF) and trans-
forming growth factor-β ] (Bork 1993).
It has long been appreciated that individual CCN
proteins are present not only as full-length proteins, but
also as fragments containing various combinations of entire
modules. For example, a fragment containing the heparin-
binding CT domain of CCN2 was purified based on
bioactivity from pig uterine flushings (Brigstock et al.
1997). Moreover, it has been shown that the amino-terminal
fragment of CCN2 (containing only the IGFBP and VWC
domains) is an effective surrogate biomarker for fibrosis
(Leask et al. 2009). Furthermore, in the case of avian
nephroblastoma, a CCN3 protein lacking the amino-
proximal (IGFBP) domain is likely to exist (Joliot et al.
1992) and in cultured human tumor cells truncated CCN3
proteins lacking the two first domains have been identified
(Kyurkchiev et al. 2004). Also, CCN3 proteins lacking the
TSP1 domain are developmentally regulated in human
kidney (Subramaniam et al. 2008). In addition, a variant
CCN4 (wisp1) protein, lacking the VWC module, has been
identified in scirrhous gastric carcinomas (Tanaka et al. 2005).
The different versions of CCN proteins are likely to arise
due to differential mRNA splicing. Although the group of
B. Perbal (Martinerie et al. 1997) detected two different
mRNA phenotypes of human CCN1 (Cyr61) in a Northern
blot analysis of tumor cells from the nervous system, and
concluded that alternative splicing might play a key role in
cancer, this hypothesis was never further investigated.
CCN1 (Cyr61) is overexpressed in tumors, and promotes
angiogenesis via integrin signaling (Lau and Lam 1999).
Hypoxia is known to induce the transcriptional activation of
pathways involved in angiogenesis, growth factor signal-
ing, and tissue invasion and is therefore a potential key
regulator of tumor growth, and hypoxia induces CCN1
mRNA expression, through a HIF response element in the
CCN1 promoter (Lin et al. 2008). In a recent report,
Hirschfeld et al. (2009) carefully analyzed the expression
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e-mail: Andrew.leask@schulich.uwo.capattern of human CCN1 in breast cancer cell lines and
tissue samples. Surprisingly, they found that breast carci-
nogenesis was accompanied by a shift in a CCN1 mRNA
which retained intron 3 toward a CCN1 mRNA which
correctly lacked intron 3. Hypoxia also resulted in the
correct splicing of CCN1 mRNA. Moreover, analyses of
matched pairs of invasive breast cancers and corresponding
non-cancerous tissue revealed a very strong induction of the
correctly spliced CCN1 transcript in invasive breast
cancers. An antibody recognizing the hinge portion of the
CCN1 molecule, located between the VWC and TSP1, was
used to recognize CCN1, CCN1 was not detected in
samples possessing the intron3-containing mRNA; indeed,
the loss of intron3 correlated with the appearance of CCN1
protein.
Whether the retention of intron 3 resulted in any CCN1
protein at all was not assessed; it is possible that the
incompletely spliced transcript may result in no CCN1
protein, or perhaps a severely truncated protein. Nonethe-
less, these data suggest that domain-specific CCN anti-
bodies may represent unique tools for cancer prognosis
(Lazar et al. 2007) but also imply that different fragments of
CCN proteins may have different functions. Moreover,
individual CCN modules interact with members of the
TGFβ family, fibronectin, integrins and heparan sulfate
containing proteoglycans (Leask and Abraham 2006). Thus
the different isoforms of individual CCN proteins may
possess different biological functions based on the modules
they contain. As an example, mice deleted for entire CCN
genes may have different phenotypes than mice deleted for
individual modules (Heath et al. 2008; Perbal 2007; Leask
2007). Indeed, full length and variant CCN proteins might
functionally compete and antagonize in normal and
pathological conditions. These considerations are important
for considering the overall in vivo effect of CCN proteins at
particular junctures of development, homeostasis and
pathologies.
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